
亚太地区天冬酰胺酶市场预测至 2028 年 - COVID-19 影响和区域分析(按类型(大肠杆菌、菊欧文氏菌、聚乙二醇化等)、应用(治疗、食品加工等)和最终用途行业(医疗保健和食品制造业)
No. of Pages: 112 | Report Code: BMIRE00027447 | Category: Life Sciences
No. of Pages: 112 | Report Code: BMIRE00027447 | Category: Life Sciences
亚太地区天冬酰胺酶市场预计将从 2022 年的 1.3243 亿美元增长到 2028 年的 3.4139 亿美元;预计 2022 年至 2028 年复合年增长率为 17.1%。
按市场划分的药品研发活动和投资增加玩家
制药行业正在飞速发展,发达国家正在大力投资开发针对各种疾病的新疗法。政府支持的行业研究经费以及开发具有高相容性和减少副作用的天冬酰胺酶的研发活动的激增预计将有助于天冬酰胺酶市场的增长。此外,市场参与者正在合作生产天冬酰胺酶,该酶被用作制药行业的活性药物成分。各国政府和天冬酰胺酶生产商正在大力投资天冬酰胺酶的研发,预计这将进一步促进未来几年的市场增长。此外,制药行业对更好稳定性的需求不断增长,以确保药品的高效储存和运输,也增加了该行业的研发活动。因此,上述所有因素预计将在预测期内推动天冬酰胺酶市场的增长。
市场概述
亚太地区天冬酰胺酶市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。此外,中国在2022年占据市场主导地位。市场的增长主要归功于不断增长的医药市场、市场参与者的不断发展以及有利的监管政策。中国人口的增长和癌症发病率的上升主要推动了该国对天冬酰胺酶等癌症治疗药物的需求,使其成为该地区的主要市场。根据世界卫生组织的报告,2020年,中国新增癌症病例约4,568,754例,因癌症死亡约3,002,899例。据《2017年全球疾病负担》报告显示,中国估计有141,317例白血病新发病例和60,010例死亡,分别占全球518,485例新发病例的27.3%和347,583例死亡的17.3%。金兰医药科技有限公司;吉万医药科技有限公司;和常州千红是中国市场上的几家主要参与者,它们向许多国家生产和供应天冬酰胺酶,用于治疗急性淋巴细胞白血病(ALL),作为多药化疗方案的一部分。因此,庞大的癌症患者群体和市场参与者对该疾病治疗的发展预计将推动该国对天冬酰胺酶的需求。
亚太地区天冬酰胺酶市场细分
亚太地区天冬酰胺酶市场根据类型、应用、最终用途行业和国家/地区进行细分。 ;
根据类型,亚太地区天冬酰胺酶市场分为大肠杆菌、菊欧文氏菌、聚乙二醇化酶等。 2022 年,大肠杆菌细分市场占据最大市场份额。根据应用,亚太地区天冬酰胺酶市场分为治疗、食品加工和其他领域。 2022年,治疗细分市场占据最大市场份额。治疗细分市场进一步分为急性淋巴细胞白血病、淋巴母细胞淋巴瘤等。根据最终用途行业,亚太地区天冬酰胺酶市场分为医疗保健和食品制造。 2022年,医疗保健领域占据了更大的市场份额。根据国家/地区,亚太地区天冬酰胺酶市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。我们的区域分析表明,中国将在 2022 年占据市场主导地位。常州千红生物制药有限公司;创意酶;爵士制药公司;梅达克有限公司;施维雅制药有限责任公司;泰姬制药有限公司;和 United Biotech (P) Limited 是亚太地区天冬酰胺酶市场的领先公司。
Strategic insights for Asia-Pacific Asparaginase involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
Report Attribute | Details |
---|---|
Market size in 2022 | US$ 132.43 Million |
Market Size by 2028 | US$ 341.39 Million |
Global CAGR (2022 - 2028) | 17.1% |
Historical Data | 2020-2021 |
Forecast period | 2023-2028 |
Segments Covered |
By 类型
|
Regions and Countries Covered | 亚太地区
|
Market leaders and key company profiles |
The regional scope of Asia-Pacific Asparaginase refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia-Pacific Asparaginase Market is valued at US$ 132.43 Million in 2022, it is projected to reach US$ 341.39 Million by 2028.
As per our report Asia-Pacific Asparaginase Market, the market size is valued at US$ 132.43 Million in 2022, projecting it to reach US$ 341.39 Million by 2028. This translates to a CAGR of approximately 17.1% during the forecast period.
The Asia-Pacific Asparaginase Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Asparaginase Market report:
The Asia-Pacific Asparaginase Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia-Pacific Asparaginase Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia-Pacific Asparaginase Market value chain can benefit from the information contained in a comprehensive market report.